RI
RIGL.US Rigel Pharmaceuticals Inc
- Market cap
- USD 808M
- P/E
- 2.7x
- P/B
- 1.85x
- ROE
- 11.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RIGL.US undervalued?
Graham numberRIGL.US trades 52.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rigel Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Rigel Pharmaceuticals Inc yet.
Rigel Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitra…
Full company profileRigel Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rigel Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 20.4M | 4.48M | 44.5M | 59.3M | 109M | 149M | 120M | 117M | 179M | 294M | 291M |
| Gross Profit | -43.1M | -41.8M | 44.2M | 58.4M | 108M | 148M | 118M | 110M | 161M | 275M | 259M |
| Operating Income | -69.7M | -79.6M | -72.7M | -69.1M | -29.0M | -12.5M | -55.6M | -20.5M | 24.2M | 125M | 70.1M |
| EBITDA | -63.0M | -77.5M | -72.1M | -65.9M | -27.7M | -11.3M | -53.9M | -17.0M | 28.5M | 132M | 77.8M |
| Net Income | -69.2M | -78.0M | -70.5M | -66.5M | -29.7M | -17.9M | -58.6M | -25.1M | 17.5M | 367M | 52.2M |
| EPS | -7.33 | -6.17 | -4.39 | -3.98 | -1.76 | -1.05 | -3.40 | -1.44 | 0.99 | 19 | 2.55 |
| Balance Sheet | |||||||||||
| Total Assets | 78.1M | 119M | 139M | 148M | 110M | 167M | 134M | 117M | 164M | 514M | 524M |
| Total Liabilities | 23.1M | 18.5M | 29.2M | 93.8M | 76.4M | 137M | 148M | 146M | 161M | 122M | 78.8M |
| Shareholders' Equity | 55.0M | 101M | 110M | 53.8M | 34.0M | 30.4M | -13.6M | -28.6M | 3.29M | 391M | 445M |
| Cash & Short-term Investments | 74.8M | 116M | 129M | 98.1M | 57.3M | 125M | 58.2M | 56.9M | 77.3M | 155M | 99.3M |
| Total Debt | 3.46M | 284K | - | 36.3M | 39.1M | 30.6M | 41.6M | 60.6M | 60.0M | 53.3M | 7.79M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -75.9M | -77.6M | -58.8M | -41.5M | -52.2M | 5.88M | -73.8M | -5.74M | 31.5M | 75.7M | 90.6M |
| Capital Expenditure | 804K | 164K | 1.11M | 1.46M | 1.26M | 627K | 450K | 15.0M | 396K | 0.00 | 289K |
| Free Cash Flow | -76.7M | -77.7M | -59.9M | -43.0M | -53.4M | 5.25M | -74.2M | -20.7M | 31.1M | 75.7M | 90.6M |
| Ratios | |||||||||||
| ROE | -125.8% | -77.5% | -64.1% | -123.7% | -87.4% | -59.0% | - | - | 531.8% | 93.8% | 11.7% |
| ROA | -88.6% | -65.5% | -50.7% | -45.1% | -26.9% | -10.7% | -43.6% | -21.4% | 10.7% | 71.5% | 10.0% |
| Net Profit Margin | -339.6% | -1,739.3% | -158.3% | -112.2% | -27.4% | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% | 17.9% |
| Debt to Equity | 0.06x | 0.00x | - | 0.67x | 1.15x | 1.01x | - | - | 18.24x | 0.14x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rigel Pharmaceuticals Inc dividends
Rigel Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jun 27, 2024.
Who owns Rigel Pharmaceuticals Inc
- Insiders 3.33%
- Institutions 95.16%
- Public & others 1.52%
- Shares outstanding 18.8M
- Free float 15.0M
Top funds holding RIGL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Avantis US Small Cap Value ETF | 945K | 5.03% | +0.78% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 556K | 2.96% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 508K | 2.71% | +2.68% | Oct 2026 |
| iShares Russell 2000 ETF | 465K | 2.47% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 202K | 1.07% | +0.21% | Aug 2026 |
| iShares Russell 2000 Value ETF | 175K | 0.93% | 0.00% | Oct 2026 |
| Nomura Healthcare Fund Class I | 160K | 0.85% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 141K | 0.75% | -0.19% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 129K | 0.69% | +15.87% | Sep 2026 |
| Vanguard Russell 2000 ETF | 107K | 0.57% | +1.16% | Sep 2026 |
| Bridge Builder Mid Cap Fund | 103K | 0.55% | +2,913.82% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 100K | 0.53% | +0.22% | Oct 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 87.9K | 0.47% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 86.3K | 0.46% | -4.57% | Sep 2026 |
| First Trust Dow Jones Sel MicroCap ETF | 81.4K | 0.43% | 0.00% | Oct 2026 |
| Indosuez Funds America Small&Mid Caps G | 78.2K | 0.42% | 0.00% | Sep 2026 |
| LSV Small Cap Value Institutional | 73.7K | 0.39% | 0.00% | Sep 2026 |
| Avantis® U.S. Small Cap Value Instl | 66.3K | 0.35% | +11.74% | Sep 2026 |
| iShares Micro-Cap ETF | 55.8K | 0.30% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 54.9K | 0.29% | +0.11% | Sep 2026 |
Top institutions holding RIGL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 1.94M | 10.33% | +9.66% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.84M | 9.81% | +18,335.04% | Jun 2026 |
| Armistice Capital, LLC | 1.67M | 8.90% | +30.63% | Jun 2026 |
| American Century Companies Inc | 1.04M | 5.56% | +40.75% | Sep 2026 |
| State Street Corp | 1.04M | 5.54% | -7.16% | Jun 2026 |
| LSV Asset Management | 787K | 4.19% | +9.11% | Sep 2026 |
| Vanguard Capital Management, LLC | 785K | 4.18% | +2.74% | Jun 2026 |
| D. E. Shaw & Co LP | 543K | 2.89% | +21.73% | Jun 2026 |
| Geode Capital Management, LLC | 483K | 2.57% | +9.66% | Jun 2026 |
| Acadian Asset Management LLC | 462K | 2.46% | -21.88% | Sep 2026 |
| Marshall Wace Asset Management Ltd | 367K | 1.96% | -38.60% | Jun 2026 |
| CM Management, LLC | 250K | 1.33% | 0.00% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 234K | 1.24% | +58.42% | Jun 2026 |
| The Goldman Sachs Group Inc | 227K | 1.21% | -48.35% | Jun 2026 |
| Two Sigma Investments LLC | 208K | 1.11% | -48.85% | Jun 2026 |
| Delaware Management Holdings Inc | 195K | 1.04% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 186K | 0.99% | +88.18% | Jun 2026 |
| Charles Schwab Investment Management Inc | 155K | 0.82% | -12.57% | Jun 2026 |
| Northern Trust Corp | 146K | 0.78% | +8.78% | Jun 2026 |
| O'Shaughnessy Asset Management LLC | 131K | 0.70% | +4.39% | Jun 2026 |
Rigel Pharmaceuticals Inc company profile
- Company name
- Rigel Pharmaceuticals Inc
- Ticker
- RIGL.US
- Exchange
- USA Stocks
- Listed since
- Nov 29, 2000
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 172
- Fiscal year end
- December
- Address
- 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 624 1100
- Website
- rigel.com
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Rigel Pharmaceuticals Inc management
8- Mr. Raul R. RodriguezPresident, CEO & Director · born 1961
- Mr. Dean L. Schorno CPAExecutive VP & CFO · born 1963
- Mr. Raymond J. Furey J.D.Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary · born 1968
- Mr. David A. SantosExecutive VP & Chief Commercial Officer · born 1963
- Dr. Alison L. Hannah M.D.Executive VP & Chief Medical Officer · born 1961
- Ms. Julie PatelSenior VP of Human Resources
- Mr. Joseph LasagaExecutive VP & Chief Business Officer · born 1975
- Mr. Tarek SallamVice President of Marketing